Aigen Investment Management, LP Revance Therapeutics, Inc. Transaction History

Aigen Investment Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $113,695 - $219,172	19,569 New	19,569 $172,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.04 Million - $1.59 Million	42,150 Added 356.06%	53,988 $1.37 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $448,204 - $861,011	-24,412 Reduced 67.34%	11,838 $381,000
Q4 2022 Feb 10, 2023	BUY	$18.32 - $30.66 $664,100 - $1.11 Million	36,250 New	36,250 $669,000
Q3 2021 Nov 12, 2021	SELL	$25.78 - $33.21 $202,785 - $261,229	-7,866 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$26.8 - $31.84 $210,808 - $250,453	7,866 New	7,866 $233,000
Q4 2020 Feb 12, 2021	SELL	$23.41 - $28.34 $613,318 - $742,479	-26,199 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$23.23 - $34.3 $344,709 - $508,977	14,839 Added 130.63%	26,199 $659,000
Q2 2020 Aug 10, 2020	BUY	$12.6 - $26.55 $43,369 - $91,385	3,442 Added 43.47%	11,360 $277,000
Q1 2020 May 08, 2020	SELL	$12.46 - $27.81 $16,135 - $36,013	-1,295 Reduced 14.06%	7,918 $117,000
Q4 2019 Feb 04, 2020	BUY	$11.66 - $20.15 $107,423 - $185,641	9,213 New	9,213 $150,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.